“We have materially strengthened our cash position, and at the same time implemented tight fiscal control that will result in a reduction of approximately 20-25% of quarterly operating cash burn in comparison with the last 2 quarters (Q1 FY2016 / Q4 FY2015).
“As a result, we have sufficient runway to deliver on important value inflexion points for our heart failure, back pain and rheumatoid arthritis programs, and to file with the FDA for approval of our pediatric graft versus host disease product candidate.
“Mesoblast’s visibility and liquidity will increase in the largest market for biotech companies as a result of our US listing.
“In addition, we intend to conclude additional and appropriate strategic partnerships,” Itescu said.
This looks perfect to me.
- Forums
- ASX - By Stock
- MSB
- Ann: Quarterly Results Filed on Form 6-K with SEC
Ann: Quarterly Results Filed on Form 6-K with SEC, page-3
-
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | 1.485 |
5 | 59100 | 1.480 |
4 | 60253 | 1.475 |
3 | 35489 | 1.470 |
1 | 34513 | 1.465 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 73626 | 3 |
1.505 | 29500 | 2 |
1.510 | 41232 | 6 |
1.515 | 123153 | 3 |
1.520 | 81763 | 5 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |